Test Price
2,800 AED✅ Home Collection Available
Familial Pancreatic Cancer‑Melanoma Syndrome (CDKN2A Gene) NGS Test in UAE | 2,800 AED
Executive Summary & Core Metrics
This CDKN2A Next‑Generation Sequencing (NGS) test delivers 99.9% diagnostic sensitivity for hereditary pancreatic cancer and melanoma risk assessment. Performed at DNA Labs UAE (DHA License 1143) in Dubai Healthcare City, the test includes full‑gene sequencing with copy number variant analysis, orthogonal Sanger confirmation, and a post‑result telephonic genetic counselling session with our Consultant Medical Genetics. VIP mobile phlebotomy for home blood collection is available daily from 8 AM to 11 PM. Insurance eligibility verification via WhatsApp at +971 54 548 8731 typically completes within minutes. Direct billing is offered for major UAE health insurers. Turnaround time is 3–4 weeks from sample receipt.
Test Overview & Methodology
The assay employs the Illumina NGS platform to sequence the entire CDKN2A coding region and intron‑exon boundaries. All clinically significant variants are confirmed by Sanger sequencing. The report includes pathogenicity classification per ACMG/AMP guidelines, lifetime risk stratification, and specific surveillance recommendations aligned with NCCN and ESMO hereditary cancer protocols.
| Feature | DNA Labs UAE CDKN2A NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Precision & Coverage | 99.9% diagnostic sensitivity; full‑gene sequencing with copy number variant analysis | Limited to selected exons/hotspots; misses large rearrangements |
| Methodology | Illumina NGS platform with orthogonal Sanger confirmation | Chain‑termination sequencing; lower throughput |
| Turnaround Time | 3–4 weeks from sample receipt | 4–8 weeks, often requiring multiple runs |
Physician Insight & Safety Protocols
“Understanding hereditary cancer predisposition is a critical step towards proactive prevention. This CDKN2A NGS test provides the granularity needed to distinguish between carriers and non‑carriers at the molecular level, enabling tailored pancreatic and dermatologic surveillance. The integrated genetic counselling pathway ensures that every patient comprehends the implications of their result within the context of their family history and lifestyle.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory & Medication Guidance
Do not discontinue any prescribed medication or alter your treatment plan without consulting your physician. This genetic test provides risk information but does not replace clinical evaluation or ongoing medical care. A positive CDKN2A result indicates elevated lifetime risk for pancreatic cancer and melanoma, not a current cancer diagnosis. A negative result does not rule out all hereditary cancer syndromes or sporadic malignancy.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Not intended for somatic (tumour‑only) testing; requires informed consent. Unsuitable for individuals unable to provide a peripheral blood or extracted DNA sample.
- Red Flag: A positive result signifies a genetically elevated lifetime risk, not an active malignancy. A negative result does not exclude all inherited cancer syndromes or sporadic cases.
- Seek Immediate Medical Attention if: You experience jaundice, new‑onset severe abdominal or back pain, unexplained weight loss, or changes in moles meeting ABCDE criteria. These signs warrant prompt clinical assessment irrespective of genetic status.
Patient FAQ & Clinical Guidance
1. What is the CDKN2A test and who should consider it?
This NGS test detects germline CDKN2A mutations that substantially increase lifetime risk for pancreatic ductal adenocarcinoma and cutaneous melanoma. It is recommended for individuals with a strong family history of pancreatic cancer, melanoma, or multiple primary malignancies, and for anyone seeking definitive hereditary risk stratification. A pre‑test and post‑test genetic counselling session is included in the service.
2. How is the test performed and what is the turnaround time?
A peripheral whole blood sample is collected by a certified phlebotomist at your home or at our Dubai Healthcare City facility. The specimen is processed on an Illumina NGS platform with Sanger confirmation of all clinically actionable variants. The full workflow from sample receipt to validated report requires 3–4 weeks. Results are delivered via a secure digital report accompanied by a telephonic consultation with our genetics team.
3. Is this test covered by insurance in the UAE?
We provide direct billing verification for UAE health insurance via WhatsApp at +971 54 548 8731, typically within minutes. Many major UAE insurers cover hereditary cancer genetic testing when medically indicated and ordered by a qualified physician. Our team will confirm your specific policy eligibility and any applicable co‑pay or deductible before sample collection.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted in transit and at rest, accessible only to authorised clinical personnel. Patient consent is obtained in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring informed decision‑making before sample collection. Our Dubai Healthcare City laboratory operates under DHA Facility License 1143 and adheres to ISO 15189 quality standards for molecular diagnostics.
Clinical & Logistical Metadata
| Test Name | Familial Pancreatic Cancer‑Melanoma Syndrome (CDKN2A Gene) NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA); VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Illumina NGS full‑gene sequencing with orthogonal Sanger confirmation and copy number variant analysis |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 94222-0 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians